Healthy subjects
Conditions
Interventions
Ingestion of herring-roe powder 15g daily for 8 weeks
Ingestion of placebo 15g daily for 8 weeks
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects whose LDL-Cho is between 120mg/dl and 180mg/dl. 2. Subjects who agree to participate in the current study with a written informed consent.
Exclusion criteria
Exclusion criteria: 1.Subjects who are under treatment and medication for chronic ailments (especially diseases related to cancer, liver, kidney, heart, digestive system, diabetes, dyslipidemia, hypertension, mental disorder, etc.) 2.Subjects with serious cerebrovascular, cardiac, hepatic, renal and / or gastrointestinal diseases, or affected with an infectious disease which is required to report to the authorities 3. Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 4. Subjects with familial hypercholesterolemia. 5. Subjects with frequent complaints of pre- or post-menopausal symptoms 6. Subjects with unusually high and/or low blood pressure, or with abnormal hematological data 7. Subjects with serious anemia 8. Subjects who are at risk of having allergic reactions to drugs or foods (especially fish-roe, soybean) 9. Subjects who take regularly thyroid drugs, or drugs containing EPA, statin, fibrate, ezetibime and/or steroids, etc. Or functional foods and/or supplements (EPA, DHA, MCT, phytosterol, sesamin, turmeric, polyphenols, dietary fiber, etc.) which would affect the blood lipids. 10. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 11. Subjects who donate either 400ml whole blood within 12 weeks or 200ml within 4 weeks, or blood component within 2 weeks prior to this study 12. Subjects who are pregnant or expected to be pregnant, or lactating during the study 13. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial 14. Any other medical reasons judged by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-Cho | — |
Secondary
| Measure | Time frame |
|---|---|
| T-Cho,HDL-Cho,TG,RLP-Cho,NEFA, Adiponectin, Leptin, Fasting blood glucose, HbA1c, Body weight, BMI, Body fat rate, OSA sleep inventory, AIS | — |
Countries
Japan
Contacts
Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.
Hokkaido Information University Center of Health Information Science (CHIS)
Outcome results
None listed